Munenobu Nogami

Munenobu Nogami

Auto-generated profile, based on publicly available information

Munenobu Nogami

Department of Radiology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in American Journal of Roentgenology
Verified
Journal Article
Closed access
YOYoshiharu Ohno
Yoshiharu Ohno
HKHisanobu Koyama
Hisanobu Koyama
MNMunenobu Nogami
Munenobu Nogami
DTDaisuke Takenaka
Daisuke Takenaka
SMSumiaki Matsumoto
Sumiaki Matsumoto
KSKazuro Sugimura
Kazuro Sugimura
OBJECTIVE. The purpose of the present study is to prospectively compare the capability of dynamic oxygen-enhanced MRI and quantitative CT for pulmonary functional loss assessment and clinical stage classification of smoking-related chronic obstructive pulmonary disease (COPD). SUBJECTS AND METHODS. Ten nonsmoking and 61 consecutive smoking-related COPD subjects underwent dynamic oxygen-enhanced MRI, CT, and pulmonary function tests. COPD subjects were classified into four clinical stages on the basis of the ATS–ERS guidelines. Wash-in time and relative enhancement ratio maps were generated by pixel-by-pixel analyses. Mean wash-in time and relative enhancement ratio were determined as averages of region of interest (ROI) measurements. CT-based functional lung volumes were measured on quantitative CT using the density-masked CT technique. For comparison of assessment capability for smoking-related functional loss, the three parameters were correlated with the percentage predicted forced expiratory volume in 1 second (%FEV1) and the percentage predicted diffusing capacity of the lung for carbon monoxide corrected for alveolar volume (%DLCO/Va). To determine the clinical stage classification capability, these parameters were statistically compared for nonsmoking subjects and all clinical stages of smoking-related COPD subjects. RESULTS. Correlation between mean wash-in time and %FEV1 (r = –0.74, p < 0.0001) and between mean relative enhancement ratio and %DLCO /Va (r = 0.66, p < 0.0001) was better than that between CT-based functional lung volume and either %FEV1 (r = 0.61, p < 0.0001) or %DLCO/Va (r = 0.56, p < 0.0001). Mean wash-in time showed a significant difference between nonsmoking and smoking-related COPD subjects at all clinical stages (p < 0.05). CONCLUSION. Dynamic oxygen-enhanced MRI has potential for pulmonary functional loss assessment and clinical stage classification of smoking-related COPD as does quantitative CT.

23 October 2009 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
MNMunenobu Nogami
Munenobu Nogami
YOYoshiharu Ohno
Yoshiharu Ohno
HKHisanobu Koyama
Hisanobu Koyama
AKAtsushi Kono
Atsushi Kono
DTDaisuke Takenaka
Daisuke Takenaka
KSKazuro Sugimura
Kazuro Sugimura
Purpose: To compare the utility of phase contrast MR imaging (PC‐MRI) for assessment of pulmonary flow and pressure estimation with that of right heart catheterization and echocardiography (cardiac US) in patients with pulmonary arterial hypertension (PAH). Materials and Methods: Twenty consecutive patients with suspected PAH underwent PC‐MRI, cardiac US, and right heart catheterization. In each patient, PC‐MRI was acquired by cine 2D‐PC method on a 1.5 Tesla scanner, and stroke volume (SV) and pulmonary arterial systolic pressure (PASP) were assessed by using the modified Bernoulli's equation. To evaluate the agreements of SV and PASP among the three methods, correlations and limits of agreement among the three methods were statistically assessed by using the Bland‐Altman's analyses. Results: The correlations and limits of agreement for SV and PASP between PC‐MRI and catheterization (r = 0.96, r2 = 0.94, 1.1 ± 6.9 mL and r = 0.94, r2 = 0.88, −3.2 ± 14.5 mmHg, respectively) were better than between cardiac US and catheterization (r = 0.01, r2 < 0.01, 8.9 ± 42.1 mL and r = 0.86, r2 = 0.72, −5.9 ± 27.7 mmHg, respectively). Conclusion: PC‐MRI is more compatible with right heart catheterization than cardiac US in pulmonary flow and pressure estimation. J. Magn. Reson. Imaging 2009;30:973–980.

28 February 2010 in Academic Radiology
Verified
Journal Article
Closed access
PDF file
HKHisanobu Koyama
Hisanobu Koyama
YOYoshiharu Ohno
Yoshiharu Ohno
YYYouichi Yamazaki
Youichi Yamazaki
MNMunenobu Nogami
Munenobu Nogami
KMKenya Murase
Kenya Murase
KSKazuro Sugimura
Kazuro Sugimura

1 January 2003 in Haigan
Verified
Journal Article
Closed access
PDF file
YOYoshiharu Ohno
Yoshiharu Ohno
MNMunenobu Nogami
Munenobu Nogami
THTakanori Higashino
Takanori Higashino
HWHirokazu Watanabe
Hirokazu Watanabe
DTDaisuke Takenaka
Daisuke Takenaka
KSKazuro Sugimura
Kazuro Sugimura
1991年のRadiologic Diagnostic Oncology Group (RDOG) の報告以来, 肺癌患者におけるMRIの臨床応用は限定された状況においてのみCTに対して相補的に用いられるにとどまってきた. 一方, 換気・血流シンチに代表される肺機i能診断法や, 2-[fluorine-18]-fluoro-2-deoxy-D-glucoseによるポジトロンエミッショントモグラフィー (FDGPET) に代表されるPET検査においては腫瘍の代謝を画像化する新たな画像診断法として脚光を浴びている. しかし, 近年のMR装置や撮像法の進歩及び各種造影剤の併用により肺癌患者のMRI診断における形態的, 機i能的評価能は飛躍的に進歩し, より正確且つ定量的評価を可能とし, 各種画像診断法の代替として潜在的に応用されうるものになりつつある.本稿においては肺癌のMRI診断について,(1) 肺腫瘤の質的診断,(2) 肺癌と二次変化の鑑別診断,(3) 縦隔浸潤診断,(4) 胸壁浸潤診断,(5) リンパ節転移診断,(6) 遠隔転移診断, 及び (7) 肺癌におけるMRIを用いた肺機能診断に関して最新の知見を踏まえて述べる. 肺癌におけるMRIの臨床応用及び研究に関しては, 様々な技術的問題点があるものの, 様々な分野での研究が進むことにより急速に進歩する可能性を秘めており, 近い将来MRIは肺癌診断の重要な一翼を担うものになると信ずる.

1 January 2005 in Haigan
Verified
Journal Article
Closed access
PDF file
YOYoshiharu Ohno
Yoshiharu Ohno
MNMunenobu Nogami
Munenobu Nogami
THTakanori Higashino
Takanori Higashino
SMSumiaki Matsumoto
Sumiaki Matsumoto
DTDaisuke Takenaka
Daisuke Takenaka
KSKazuro Sugimura
Kazuro Sugimura
CT及びMRIにおける近年の技術革新には目覚しいものがあり, 従来の高分解能CTやMRIにおけるT1強調像及びT2強調像にて確立された画像診断法にくわえて, 新たにマルチディテクターCT (multidetector-row CT: MDCT) によって得られた高精細なvolume dataを用いた様々な再構成画像や各種画像法によって得られた新たなMRIによる形態・機能診断が可能になりその臨床応用も進んできている. 本稿においては肺癌の最新のCT及びMRI診断について, (1) 肺結節の質的診断や肺腺癌の分化度の推定, (2) TNM因子診断, 及び (3) 肺癌におけるMRIを用いた肺機能診断に関して最新の知見を踏まえて述べる.